Prior Authorization Group Description

Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION 5HT3 ANTI-NAUSEA AGENT BVD DETERMINATIONDRUG NAME GRANISETRON HCL | GRANISOL | ONDANSETRON HCL | ONDANSETRON ODTCOVERED USES THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATIONOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION ABATACEPTDRUG NAME ORENCIACOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION RENEWAL: RHEUMATOID ARTHRITIS/JUVENILE IDIOPATHIC ARTHRITIS: EXPERIENCED OR MAINTAINED 20% OR GREATER IMPROVEMENT IN TENDER AND SWOLLEN JOINT COUNT.AGE RESTRICTIONSPRESCRIBER RESTRICTIONS PRESCRIBED BY OR SUPERVISED BY A RHEUMATOLOGIST.COVERAGE DURATION INITIAL: 3 MONTHS RENEWAL: 12 MONTHSOTHER CRITERIA INITIAL: FOR RHEUMATOID ARTHRITIS : TRIAL OF AT LEAST ONE OF THE FOLLOWING: ENBREL, HUMIRA, REMICADE, CIMZIA, OR SIMPONI AND TRIAL/FAILURE OF AT LEAST ONE DMARD (METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE). FOR JUVENILE IDIOPATHIC ARTHRITIS: TRIAL OF AT LEAST ONE OF THE FOLLOWING: ENBREL, HUMRIA, OR REMICADE AND TRIAL/FAILURE OF AT LEAST ONE DMARD (METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE).NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION ABATACEPT SQDRUG NAME ORENCIACOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION RENEWAL: RHEUMATOID ARTHRITIS: EXPERIENCED OR MAINTAINED 20% OR GREATER IMPROVEMENT IN TENDER AND SWOLLEN JOINT COUNT.AGE RESTRICTIONS 18 YEARS OR OLDER.PRESCRIBER RESTRICTIONS PRESCRIBED BY OR SUPERVISED BY A RHEUMATOLOGIST.COVERAGE DURATION INITIAL: 3 MONTHS RENEWAL: 12 MONTHSOTHER CRITERIA INITIAL: RHEUMATOID ARTHRITIS: TRIAL OF AT LEAST ONE OF THE FOLLOWING: ENBREL, HUMIRA, REMICADE, CIMZIA, OR SIMPONI AND TRIAL/FAILURE OF AT LEAST ONE DMARD (METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE).NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION ABIRATERONEDRUG NAME ZYTIGACOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION ADALIMUMABDRUG NAME HUMIRACOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION INITIAL: PLAQUE PSORIASIS: MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 10 PERCENT BODY SURFACE AREA OR PSORIATIC LESIONS AFFECT THE HANDS, FEET, OR GENITAL AREA. RENEWAL: RHEUMATOID ARTHRITIS/JUVENILE IDOPATHIC ARTHRITIS/PSORIATIC ARTHRITIS: EXPERIENCED OR MAINTAINED 20 PERCENT IMPROVEMENT IN TENDER OR SWOLLEN JOINT COUNT WHILE ON THERAPY. /ANKYLOSING SPONDYLITIS: EXPERIENCED OR MAINTAINED IMPROVEMENT OF AT LEAST 50 PERCENT OR 2 UNITS IN THE BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX (BASDAI). PLAQUE PSORIASIS: ACHIEVED OR MAINTAINED CLEAR OR MINIMAL DISEASE OR A DECREASE IN PSORIASIS AREA AND SEVERITY INDEX (PASI) OF AT LEAST 50% OR MORE. AGE RESTRICTIONSPRESCRIBER RESTRICTIONS PRESCRIBED BY OR SUPERVISED BY A RHEUMATOLOGIST, DERMATOLOGIST, GASTROENTEROLOGIST.COVERAGE DURATION INITIAL: 3 MONTHS. RENEWAL: 12 MONTHS.OTHER CRITERIA INITIAL: RHEUMATOID ARTHRITIS/JUVENILE IDIOPATHIC ARTHRITIS: TRIAL/FAILURE OF AT LEAST ONE DMARD (METHOTREXATE, LEFLUNOMIDE, NHE_PA_Webfile HYDROXYCHLOROQUINE, OR SULFASALAZINE) AND CURRENTLY TAKING OR HAVE A CONTRAINDICATION TO THE USE OF METHOTREXATE. PSORIATIC ARTHRITIS: TRIAL/FAILURE OF AT LEAST ONE DMARD (METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE). PLAQUE PSORIASIS: TRIAL/FAILURE OF ONE OR MORE FORMS OF PREFERRED THERAPY (PUVA, UVG, ACITRETIN, METHOTREXATE, OR CYCLOSPORIN). CROHN'S DISEASE: TRIAL/FAILURE OF ONE OR MORE CONVENTIONAL THERAPIES SUCH AS CORTICOSTEROIDS (BUDESONIDE, MEHTYLPREDNISOLONE), AZATHIOPRINE, MERCAPTOPURINE, METHOTREXATE, OR MESALAMINE. RENEWAL: RHEUMATOID ARTHRITIS CURRENTLY ON OR HAS CONTRAINDICATION TO THE USE OF METHOTREXATE. RHEUMATOID ARTHRITIS/PSORIATIC ARTHRITIS/ ANKYLOSING SPONDYLITIS: FOR HUMIRA 40 MG EVERY WEEK: TRY/FAIL AT LEAST A 3 MONTH TRIAL OF HUMIRA 40MG EVERY OTHER WEEK.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION ANAKINRADRUG NAME KINERETCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION RENEWAL: RHEUMATOID ARTHRITIS: EXPERIENCED OR MAINTAINED 20% OR GREATER IMPROVEMENT IN TENDER AND SWOLLEN JOINT COUNT.AGE RESTRICTIONS 18 YEARS OR OLDERPRESCRIBER RESTRICTIONS PRESCRIBED BY OR SUPERVISED BY A RHEUMATOLOGIST.COVERAGE DURATION INITIAL: 3 MONTHS RENEWAL: 12 MONTHSOTHER CRITERIA INITIAL: RHEUMATOID ARTHRITIS: TRIAL/FAILURE OF HUMIRA OR CIMZIA AND AT LEAST ONE DMARD (METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE).NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION APREPITANT BVD DETERMINATIONDRUG NAME EMENDCOVERED USES THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATIONOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION AROMATASE INHIBITORSDRUG NAME ANASTROZOLE | EXEMESTANE | LETROZOLECOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION AXITINIBDRUG NAME INLYTACOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA TRIAL OF AT LEAST ONE SYSTEMIC THERAPY FOR THE TREATMENT OF RCC SUCH AS NEXAVAR (SORAFENIB), TORISEL (TEMSIROLIMUS), SUTENT (SUNITINIB), VOTRIENT (PAZOPANIB), OR AVASTIN (BEVACIZUMAB) IN COMBINATION WITH INTERFERON.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION BARBITURATESDRUG NAME BUTISOL SODIUM | PHENOBARBITALCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION PHENOBARB: SEIZURES LIFETIME. OTHER: 6 MOS.OTHER CRITERIA ALL MEMBERS: DIAGNOSIS IS LIMITED TO MEDICAL CONDITIONS OF EPILEPSY (SEIZURES), CANCER, OR A CHRONIC MENTAL HEALTH DISORDER. MEMBERS 65 YEARS OF AGE OR OLDER: REQUESTS FOR INSOMNIA REQUIRE TRIAL OR CONTRAINDICATION TO ROZEREM OR SILENOR.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION BEDAQUILINE FUMARATEDRUG NAME SIRTUROCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 24 WEEKSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION BELIMUMABDRUG NAME BENLYSTACOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION AUTOANTIBODY POSITIVE LUPUS TEST.AGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA INITIAL: SELENA-SELDAI SCORE GREATER THAN OR EQUAL TO 6. RENEWAL: MAINTAIN AT LEAST A 4 POINT REDUCTION IN SELENA-SELDAI SCORE FROM BASELINE. MEMBER IS CURRENTLY TAKING CORTICOSTEROIDS, ANTIMALARIALS, NSAIDS, OR IMMUNOSUPPRESSIVE AGENTS. NO APPROVAL FOR DIAGNOSIS OF SEVERE ACTIVE LUPUS NEPHRITIS OR SEVERE CENTRAL NERVOUS SYSTEM LUPUS OR CONCURRENT USE OF BIOLOGIC AGENTS, OR INTRAVENOUS CYCLOPHOSAMIDE.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION BOCEPREVIRDRUG NAME VICTRELISCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIA DETECTABLE HCV RNA LEVEL/VIRAL LOAD OR HCV RNA LEVEL/VIRAL LOAD GREATER THAN OR EQUAL TO 100 IU/ML AFTER TRIPLE THERAPY.REQUIRED MEDICAL INFORMATION CHRONIC HEPATITIS C, GENOTYPE 1. NATIVE PATIENT: HCV RNA LEVEL/VIRAL LOAD AT TRIPLE THERAPY TREATMENT WEEK 4, 8, 12, AND 24 OF BOCEPREVIR THERAPY. PARTIAL RESPONDER, NULL RESPONDER, OR RELAPSER: HCV RNA LEVEL/VIRAL LOAD AT WEEK 8 AND 20 OF BOCEPREVIR THERAPY.AGE RESTRICTIONS PATIENT 18 YEARS OF AGE OR OLDER.PRESCRIBER RESTRICTIONS GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (E.G. HEPATOLOGIST) OR SPECIALLY TRAINED GROUP (E.G. EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES).COVERAGE DURATION INITIAL: UP TO 12 WKS. RENEWAL: W/ CIRRHOSIS UP TO 32 WKS, W/O CIRRHOSIS UP TO 20 WKS.OTHER CRITERIA CONCURRENT USE OF RIBAVIRIN AND PEGINTERFERON ALFA. APPROVAL CONSIDERATION GIVEN FOR PATIENTS WITH CIRRHOSIS, POOR INTERFERON RESPONSE AT TREATMENT WEEK 4, LESS THAN 2-LOG10 HCV RNA DECLINE BY NHE_PA_Webfile TREATMENT WEEK 12 DURING PRIOR THERAPY WITH PEGINTERFERON/RIBAVIRIN, DECTECTABLE HCV RNA LEVEL AT TREATMENT WEEK 8 BUT UNDECTABLEABLE LEVEL AT WEEK 24, FAILURE (PARITAL RESPONDER OR RELAPSER) OF PRIOR TRIAL OF RIBAVIRIN AND PEGINTERFERON THERAPY. TREATMENT WITH BOCEPREVIR WILL NOT BE APPROVED FOR A PATIENT WHO HAS FAILED SHORT TRIAL OR HAS CONTRAINDICATION TO TELAPREVIR (INCIVEK) OR HAS PREVIOUS FAILURE OF FULL COURSE OF TRIPLE THERAPY WITH TELAPREVIR (INCIVEK) OR BOCEPREVIR (VICTRELIS) OR HAS HAD A FAILURE OF PRIOR COURSE OF PEGINTERFERON AND RIBAVIRIN AS A NULL RESPONDER OR CURRENTLY TAKING CARBAMAZEPINE, PHENOBARBITAL, PHENYTOIN, OR RIFAMPIN OR HAS A CO- INFECTION WITH HEPATITIS B, OR HISTORY OF PREVIOUS SOLID ORGAN TRANSPLANT.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION BOSUTINIBDRUG NAME BOSULIFCOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA TRIAL OF OR CONTRAINDICATION TO GLEEVEC, SPRYCEL, OR TASIGNA.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION BOTULINUM NEUROTOXINDRUG NAME BOTOX | DYSPORTCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIA COSMETIC DIAGNOSIS: WRINKLES.REQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA MIGRAINE HEADACHE: TRIAL OF TWO OF THE FOLLOWING: BETA BLOCKERS, TRICYCLIC ANTIDEPRESSANTS, OR VALPROIC ACID. BLEPHAROSPASM: TRIAL OF BOTOX.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION C1 ESTERASE INHIBITORDRUG NAME CINRYZECOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONS HEMATOLOGIST, IMMUNOLOGISTCOVERAGE DURATION 12 MONTHSOTHER CRITERIA TRIAL OF OR INTOLERABLE SIDE EFFECTS TO DANAZOL.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION CABOZANTINIBDRUG NAME COMETRIQCOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION CALCINEURIN INHIBITORSDRUG NAME ELIDEL | PROTOPICCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIA NOT TRIED/FAILED OR INTOLERABLE ADVERSE EFFECTS TO TOPICAL CORTICOSTEROIDSREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONS ELIDEL 1% AND PROTOPIC 0.03%: 2 YEARS OR OLDER. PROTOPIC 0.1%: OVER 14 YEARS.PRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION CERTOLIZUMAB PEGOLDRUG NAME CIMZIACOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION RENEWAL: RHEUMATOID ARTHRITIS: EXPERIENCED OR MAINTAINED 20% OR GREATER IMPROVEMENT IN TENDER AND SWOLLEN JOINT COUNT.AGE RESTRICTIONSPRESCRIBER RESTRICTIONS PRESCRIBED BY OR SUPERVISED BY A GASTROENTEROLOGIST OR RHEUMATOLOGIST.COVERAGE DURATION INITIAL: 3 MONTHS RENEWAL: 12 MONTHSOTHER CRITERIA FOR MODERATE TO SEVERE CROHN'S DISEASE: TRIAL/FAILURE OF ONE OR MORE CONVENTIONAL THERAPIES FOR CROHN'S DISEASE SUCH AS CORTICOSTEROIDS, AZATHIOPRINE, MERCAPTOPURINE, METHOTREXATE, OR MESALAMINE. FOR MODERATE TO SEVERE RHEUMATOID ARTHRITIS: TRIAL/FAILURE OF AT LEAST ONE DMARD AGENT (METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE) AND CURRENTLY TAKING OR HAVE A CONTRAINDICATION TO THE USE OF METHOTREXATE. RENEWAL: RHEUMATOID ARTHRITIS: CURRENTLY ON OR HAS CONTRAINDICATION TO THE USE OF METHOTREXATE.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION CHENODIOLDRUG NAME CHENODALCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CEREBROTENDINOUS XANTHOMATOSIS.EXCLUSION CRITERIA RADIOLUCENT GALLSTONES: NO FAILED TREATMENT WITH URSODIOLREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION CHOLINESTERASE INHIBITORSDRUG NAME ARICEPTCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION MINI MENTAL STATE EXAM (MMSE) SCORE OF 26 OR LESSAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION CLOBAZAMDRUG NAME ONFICOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONS 2 YEARS OF AGE OR OLDERPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA TRIAL OF LAMOTRIGINE OR TOPIRAMATE.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION CORTICOSTEROID BVD DETERMINATIONDRUG NAME A-HYDROCORT | CORTISONE ACETATE | DEXAMETHASONE | DEXAMETHASONE SODIUM PHOSPHATE | HYDROCORTISONE | METHYLPREDNISOLONE | METHYLPREDNISOLONE ACETATE | METHYLPREDNISOLONE SOD SUCC | PREDNISOLONE SODIUM PHOSPHATE | PREDNISONE | PREDNISONE INTENSOL | SOLU-CORTEF | SOLU-MEDROL | VERIPRED 20COVERED USES THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATIONOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION CORTICOTROPINDRUG NAME H.P. ACTHARCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. EXCLUSION CRITERIA USED FOR DIAGNOSTIC PURPOSES. ACUTE EXACERBATION OF MULTIPLE SCLEROSIS: IV ACCESS OR IV ACCESS CAN BE OBTAINED.REQUIRED MEDICAL INFORMATIONAGE RESTRICTIONS INFANTILE SPASMS: LESS THAN 2 YEARS OF AGE.PRESCRIBER RESTRICTIONSCOVERAGE DURATION INFANTILE SPASMS: 28 DAYS. MULTIPLE SCLEROSIS: 21 DAYS. ALL OTHERS: 12 MONTHS.OTHER CRITERIA ALL DIAGNOSIS EXCEPT INFANTILE SPASMS REQUIRE PRIOR USE OF IV CORTICOSTEROIDS.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION CRIZOTINIBDRUG NAME XALKORICOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION LOCALLY ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER IS ANAPLASTIC LYMPHOMA KINASE POSITIVE.AGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION CYCLOPHOSPHAMIDE BVD DETERMINATIONDRUG NAME CYCLOPHOSPHAMIDECOVERED USES THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATIONOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION CYCLOSPORINE OPHTHALMICDRUG NAME RESTASISCOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION KERATOCONJUNCTIVITIS SICCA (KCS) OR DRY EYE DISEASE.AGE RESTRICTIONSPRESCRIBER RESTRICTIONS PRESCRIBED BY OR SUPERVISED BY A OPHTHALMOLOGIST, OPTOMETRIST, OR RHEUMATOLOGIST.COVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION DABIGATRANDRUG NAME PRADAXACOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION DABRAFENIB MESYLATEDRUG NAME TAFINLARCOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION DALFAMPRIDINEDRUG NAME AMPYRACOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION WALKING DISABILITY SUCH AS MILD TO MODERATE BILATERAL LOWER EXTREMITY WEAKNESS OR UNILATERAL WEAKNESS PLUS LOWER EXTREMITY OR TRUNCAL ATAXIA.AGE RESTRICTIONSPRESCRIBER RESTRICTIONS NEUROLOGISTCOVERAGE DURATION INITIAL: 3 MONTHS. RENEWAL: 12 MONTHSOTHER CRITERIA RENEWAL: PATIENT HAS EXPERIENCED OR MAINTAINED AT LEAST 15% IMPROVEMENT IN WALKING ABILITY.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION DENOSUMABDRUG NAME PROLIACOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION A PATIENT WITH EITHER A HISTORY OF OSTEOPORTIC FRACTURE(S) OR GREATER THAN OR EQUAL TO TWO FACTORS FOR FRACTURE (E.G. HISTORY OF MULTIPLE RECENT LOW TRAUMA FRACTURES, BMD T-SCORE LESS THAN OR EQUAL TO -2.5, CORTICOSTEROID USE, OR USE OF GNRH ANALOGS), OR FAILED AN ADEQUATE TRIAL OF BISPHOSPHONATES, IS INTOLERANT, OR HAS A CONTRAINDICATION TO BISPHOSPHONATES.AGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION DENOSUMAB-XGEVADRUG NAME XGEVACOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIA DIAGNOSIS OF MULTIPLE MYELOMAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION DIMETHYL FUMARATEDRUG NAME TECFIDERACOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONS 18 YEARS OF AGE AND OLDERPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA TRIAL OF OR CONTRAINDICATION TO REBIF AND COPAXONE. APPROVAL CONSIDERATION GIVEN TO MEMBERS WITH RAPID PROGRESSION OF DISEASE WHILE ON INTERFERON THERAPY (SUCH AS AVONEX, BETASERON, EXTAVIA) OR COPAXONE.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION ELTROMBOPAGDRUG NAME PROMACTACOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION INITIAL:1 MONTH RENEWAL: NO RESPONSE AFTER INITIAL:1 MONTH AT MAX DOSE, IF RESPONSE: 12 MONTHS.OTHER CRITERIA INITIAL: TRIAL OF OR CONTRAINDICATION TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR AN INSUFFICIENT RESPONSE TO SPLENECTOMY. RENEWAL: PATIENT HAS A CLINICAL RESPONSE AS DEFINED BY AN INCREASE IN PLATELET COUNT OF GREATER THAN OR EQUAL TO 50 X10^9/L (GREATER THAN OR EQUAL TO 50,0000 PER UL) AT THE MAX DOSE OF 75MG PER DAY FOR 4 WEEKS.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION ENDOTHELIN RECEPTOR ANTAGONISTSDRUG NAME LETAIRIS | TRACLEERCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION DIAGNOSIS OF PULMONARY ARTIERAL HYPERTENTION GREATER OR EQUAL TO NYHA/WHO FUNCTIONAL CLASS II.AGE RESTRICTIONSPRESCRIBER RESTRICTIONS CARDIOLOGIST OR PULMONOLOGIST.COVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION ENZALUTAMIDEDRUG NAME XTANDICOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA TRIAL OF OR CONTRAINDICATION TO DOCETAXEL.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORSDRUG NAME TARCEVACOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION NON SMALL CELL LUNG CANCER: EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVING MUTATIONS. AGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA FOR NON SMALL CELL LUNG CANCER: IF NO EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVING MUTATIONS PATIENT WILL NEED TRIAL OF OR CONTRAINDICATION TO IV CHEMOTHERAPY. CURRENT OR PREVIOUS TREATMENT/BENEFIT FROM IRESSA CAN CONTINUE TREATMENT WITH DRUG. IF NOT WILL NEED TRIAL OF TARCEVA. FOR PANCREATIC CANCER: TARCEVA USED IN COMBINATION WITH GEMCITABINE.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION ERIBULINDRUG NAME HALAVENCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA PREVIOUS TREATMENT WITH AN ANTHRACYCLINE (DAUNORUBICIN, DOXORUBICIN, IDARUBICIN, EPIRUBICIN, OR MITOXANTRONE) AND A TAXANE (DOCETAXEL OR PACLITAXEL).NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION ERYTHROPOIESIS STIMULATING AGENTS - ARANESPDRUG NAME ARANESPCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION CHRONIC RENAL FAILURE: HEMOGLOBIN LEVELS LESS THAN 10 G/DL IF NOT ON DIALYSIS AND LESS THAN 11 G/DL IF ON DIALYSIS OR HEMOGLOBIN HAS REACHED 11 G/DL IF ON DIALYSIS AND DOSE REDUCTION/INTERRUPTION IS REQUIRED TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS OR HEMOGLOBIN HAS REACHED 10 G/DL IF NOT ON DIALYSIS AND DOSE REDUCTION/INTERRUPTION IS REQUIRED TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS. ANEMIA DUE TO EFFECT OF CONCOMITANTLY ADMINISTERED CANCER CHEMOTHERAPY: HEMOGLOBIN LEVELS BETWEEN 10 AND 12 G/DL OR HEMOGLOBIN LEVEL LESS THAN 11 G/DL OR HEMOGLOBIN LEVEL DECREASED AT LEAST 2 G/DL BELOW THEIR BASELINE.AGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION ANEMIA DUE TO MYELOSUPPRESSIVE CHEMO/CKD WITHOUT DIALYSIS: 12 MONTHS.OTHER CRITERIA ALL INDICATIONS: TRIAL OF PROCRIT. PART D MEMBER RECEIVING DIALYSIS OR IDENTIFIED AS A PART D END STAGE RENAL DISEASE MEMBER: PAYS UNDER PART B.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION ERYTHROPOIESIS STIMULATING AGENTS - EPOETIN ALFADRUG NAME EPOGEN | PROCRITCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. ADDITIONAL OFF LABEL ANEMIA IN HEPATITIS C BEING TREATED IN COMBINATION WITH RIBAVIRIN AND AN INERFERON ALFA OR PEGINTERFERON ALFA.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION CHRONIC RENAL FAILURE HEMAGLOBIN LEVELS LESS THAN 10 G/DL IF NOT ON DIALYSIS AND LESS THAN 11 G/DL IF ON DIALYSIS OR HEMOGLOBIN HAS REACHED 11 G/DL IF ON DIALYSIS AND DOSE REDUCTION/INTERRUPTION IS REQUIRED TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS OR HEMOGLOBIN HAS REACHED 10 G/DL IF NOT ON DIALYSIS AND DOSE REDUCTION/INTERRUPTION IS REQUIRED TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS. ANEMIA DUE TO EFFECT OF CONCOMITANTLY ADMINISTERED CANCER CHEMOTHERAPY: HEMOGLOBIN LEVELS BETWEEN 10 AND 12 G/DL OR HEMOGLOBIN LEVEL LESS THAN 11 G/DL OR HEMOGLOBIN LEVEL DECREASED AT LEAST 2 G/DL BELOW THEIR BASELINE. ZIDOVUDINE THERAPY: HEMOGLOBIN LEVEL BETWEEN 10 AND 12 G/DL OR HEMOGLOBIN LESS THAN 10 G/DL. ELECTIVE, NONCARDIAC, NONVASCULAR SURGERY: HEMOGLOBIN LESS THAN 13 G/DL. CONCURRENT HEPATITIS C TREATMENT: HEMOGLOBIN LESS BETWEEN 10 AND 12 G/DL FOR PATIENTS CURRENTLY TAKING REQUESTED MEDICATION OR CONTRAINDICATION TO RIBAVIRIN DOSE REDUCTION AND HEMOGLOBIN LESS THAN 10 G/DL FOR NEW STARTS.AGE RESTRICTIONSPRESCRIBER RESTRICTIONSNHE_PA_Webfile COVERAGE DURATION ANEMIA FROM MYELOSUPPRESSIVE CHEMO/CKD W/O DIALYSIS/ZIDOVUDINE:12 MOS. SURGERY:1 MO. HEP C:6 MOS.OTHER CRITERIA ALL INDICATIONS: TRIAL OF PROCRIT. PART D MEMBER RECEIVING DIALYSIS OR IDENTIFIED AS A PART D END STAGE RENAL DISEASE MEMBER: PAYS UNDER PART B.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION ESRD BVD DETERMINATIONDRUG NAME BONIVA | CALCITRIOL | CUBICIN | HECTOROL | HEPARIN SODIUM | LEVOCARNITINE | LIDOCAINE | LIDOCAINE HCL | LIDOCAINE-PRILOCAINE | MIACALCIN | PAMIDRONATE DISODIUM | VANCOMYCIN HCL | ZEMPLARCOVERED USES THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATIONOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION ETANERCEPTDRUG NAME ENBRELCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION INITIAL: PLAQUE PSORIASIS: MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 10 PERCENT BODY SURFACE AREA OR PSORIATIC LESIONS AFFECT THE HANDS, FEET, OR GENITAL AREA.RENEWAL: RHEUMATOID ARTHRITIS/JUVENILE IDIOPATHIC ARTHRITIS/PSORIATIC ARTHRITIS: EXPERIENCED OR MAINTAINED 20 PERCENT IMPROVEMENT IN TENDER OR SWOLLEN JOINT COUNT WHILE ON THERAPY. /ANKYLOSING SPONDYLITIS: EXPERIENCED OR MAINTAINED IMPROVEMENT OF AT LEAST 50 PERCENT OR 2 UNITS IN THE BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX (BASDAI). PLAQUE PSORIASIS: ACHIEVED OR MAINTAINED CLEAR OR MINIMAL DISEASE OR A DECREASE IN PSORIASIS AREA AND SEVERITY INDEX (PASI) OF AT LEAST 50% OR MORE. AGE RESTRICTIONSPRESCRIBER RESTRICTIONS PRESCRIBED BY OR SUPERVISED BY A RHEUMATOLOGIST OR DERMATOLOGIST.COVERAGE DURATION INITIAL: 3 MONTHS RENEWAL: 12 MONTHSOTHER CRITERIA INITIAL: FOR RHEUMATOID ARTHRITIS: TRIAL OF HUMIRA OR CIMIZIA AND TRIAL/FAILURE TO AT LEAST ONE DMARD AGENT (METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE). FOR JUVENILE NHE_PA_Webfile IDOPATHIC ARTHRITIS: TRIAL OF HUMIRA AND TRIAL/FAILURE TO AT LEAST ONE DMARD AGENT (METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE). FOR ANKYLOSING SPONDYLITIS: TRIAL OF HUMIRA. FOR PSORIATIC ARTHRITIS: TRIAL OF HUMIRA AND TRIAL/FAILURE OF AT LEAST ONE DMARD (METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE). FOR MODERATE TO SEVERE PLAQUE PSORIASIS: TRIAL OF HUMIRA AND TRIAL/FAILURE OF ONE OR MORE FORMS OF PREFERRED THERAPY (PUVA, UVG, ACITRETIN, METHOTREXATE, OR CYCLOSPORINE).NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION EVEROLIMUSDRUG NAME AFINITOR | AFINITOR DISPERZCOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA ADVANCED RENAL CELL CARCINOMA (RCC): TRIAL OF OR CONTRAINDICATION TO SUTENT OR NEXAVAR.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION FENTANYL TRANSDERMAL PATCHDRUG NAME FENTANYLCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA TRIAL OF OR CONTRAINDICATION TO AT LEAST ONE SUSTAINED-RELEASE MORPHINE PRODUCT. EVERY 48 HOUR DOSING CONSIDERED FOR PATIENTS WHO FAIL EVERY 72 HOUR DOSING. NO APPROVAL WHEN PRESCRIBED FOR AS NEEDED DOSAGE FREQEUNCY.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION FENTANYL TRANSMUCOSAL AGENTSDRUG NAME FENTANYL CITRATECOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION CANCER: ON A MAINTENANCE DOSE OF CONTROLLED- RELEASE PAIN MEDICATION, AND EITHER A TRIAL AND FAILURE OF 1 IMMEDIATE-RELEASE ORAL PAIN AGENT OR DIFFICULTY SWALLOWING TABLETS/CAPSULESAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 6 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION GLP-1 ANALOGSDRUG NAME VICTOZA 3-PAKCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA FAILURE TO REACH TREATMENT GOALS WITH METFORMIN, METFORMIN ER, GLYBURIDE/METFORMIN, GLIPIZIDE/METFORMIN, A FORMULARY SULFONYLUREA (GLYBURIDE, GLIPIZIDE), PIOGLITAZONE (ACTOS), PIOGLITAZONE/METFORMIN (ACTOSPLUS MET), OR PIOGLITAZONE/GLIMEPIRIDE (DUETACT) AND EXENATIDE EXTENDED RELEASE (BYDUREON).NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION GLYCEROL PHENYLBUTYRATEDRUG NAME RAVICTICOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONS 2 MONTHS OF AGE AND OLDERPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA TRIAL OF OR CONTRAINDICATION TO SODIUM PHENYLBUTYRATE (BUPHENYL).NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION GOLIMUMABDRUG NAME SIMPONICOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION RENEWAL: ACTIVE RHEUMATOID ARTHRITIS/PSORIATIC ARTHRITIS: GREATER THAN 20% IMPROVEMENT IN TENDER JOINT COUNT AND SWOLLEN JOINT COUNT. ANKYLOSING SPONDYLITIS: GREATER THAN 20% IMPROVEMENT IN ANKYLOSING SPONDYLITIS (ASAS20) CRITERIA.AGE RESTRICTIONS 18 YEARS OR OLDERPRESCRIBER RESTRICTIONS PRESCRIBED BY OR SUPERVISED BY A RHEUMATOLOGIST OR DERMATOLOGIST.COVERAGE DURATION INITIAL: 3 MONTHS RENEWAL: 12 MONTHSOTHER CRITERIA ACTIVE RHEUMATOID ARTHRITIS INITIAL: TRIAL OF HUMIRA OR CIMZIA AND TRIAL/FAILURE OF AT LEAST ONE DMARD AGENT (METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE). PSORIATIC ARTHRITIS: TRIAL OF HUMIRA AND TRIAL/FAILURE OF AT LEAST ONE DMARD (METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE). ANKYLOSING SPONDYLITIS: TRIAL OF HUMIRA.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION HEPATITIS A VACCINE (INACTIVATED) BVD DETERMINATIONDRUG NAME HAVRIX | VAQTACOVERED USES THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATIONOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION HEPATITIS B VACCINE BVD DETERMINATIONDRUG NAME ENGERIX-B | ENGERIX-B ADULT | RECOMBIVAX HBCOVERED USES THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATIONOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION IMIQUIMOD - ALDARADRUG NAME IMIQUIMODCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. ADDITIONAL OFF LABEL COVERAGE FOR ACTINIC KERATOSIS NOT LIMITED TO THE FACE AND SCALP IN NON-IMMUNOCOMPETENT PATIENTS, MOLLUSCUM CONTAGIOSUM, AND LETIGO MALIGNA.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONS EXTERNAL GENITAL OR PERIANAL WARTS: GREATER THAN OR EQUAL TO 12 YEARS OF AGE. ACTINIC KERATOSIS: GREATER THAN OR EQUAL TO 18 YEARS OF AGE.PRESCRIBER RESTRICTIONS ACTINIC KERATOSIS: DERMATOLOGIST ONLY. SUPERFICIAL BASAL CELL CARCINOMA/LETIGO MALIGNA: DERMATOLOGIST OR ONCOLOGIST ONLY.COVERAGE DURATION 4 MONTHSOTHER CRITERIA CRITERIA APPLIES TO NEW STARTS ONLY. ACTINIC KERATOSIS: TRIAL OF TOPICAL 5-FLUOROURACIL. ACTINIC KERATOSIS BRAND DRUG REQUEST: TRIAL/FAILURE OF GENERIC IMIQUIMOD 5%. SUPERFICIAL BASAL CELL CARCINOMA: LESS THAN 2CM IN SIZE AND NOT ON THE FACE. MOLLUSCUM CONTAGISOUM LIMITED TO THE FACE.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION IMIQUIMOD - ZYCLARADRUG NAME ZYCLARACOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONS EXTERNAL GENITAL OR PERIANAL WARTS: GREATER THAN OR EQUAL TO 12 YEARS OF AGE. ACTINIC KERATOSIS: GREATER THAN 18 YEARS OF AGE.PRESCRIBER RESTRICTIONS DERMATOLOGIST SUPERVISION.COVERAGE DURATION ACTINIC KERATOSIS: 2 MONTHS. ALL OTHER DIAGNOSIS: 4 MONTHSOTHER CRITERIA CRITERIA APPLIES TO NEW STARTS ONLY. EXTERNAL GENITAL OR PERIANAL WARTS: TRIAL OR CONTRAINDICATION TO PODOFLOX OR GENERIC IMIQUIMOID 5%. ACTINIC KERATOSIS: TRIAL OR CONTRAINDICATION TO TOPICAL 5- FLUOROURACIL AND GENERIC IMIQUIMOID 5%.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION IMMUNE GLOBULIN BVD DETERMINATIONDRUG NAME CARIMUNE NF NANOFILTERED | GAMASTAN S-D | GAMMAGARD LIQUID | GAMMAPLEX | GAMUNEX-C | PRIVIGENCOVERED USES THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATIONOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION IMMUNOSUPPRESSANT BVD DETERMINATIONDRUG NAME ASTAGRAF XL | AZATHIOPRINE | AZATHIOPRINE SODIUM | CELLCEPT | CYCLOSPORINE | CYCLOSPORINE MODIFIED | GENGRAF | MYCOPHENOLATE MOFETIL | MYFORTIC | NULOJIX | PROGRAF | RAPAMUNE | SIMULECT | TACROLIMUS | ZORTRESSCOVERED USES THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATIONOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION INFLIXIMABDRUG NAME REMICADECOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION INITIAL: PLAQUE PSORIASIS: MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 10 PERCENT BODY SURFACE AREA OR PSORIATIC LESIONS AFFECT THE HANDS, FEET, OR GENITAL AREA. RENEWAL: RHEUMATOID/PSORIATIC ARTHRITIS: GREATER THAN 20% IN TENDER JOINT COUNT AND SWOLLEN JOINT COUNT. FOR PLAQUE PSORIASIS: PASI OF GREATER THAN 50% OR SIGNIFCANT IMPROVEMENT IN QUALITY OF LIFE OBSERVED BY PHYSICIAN AND PATIENT. FOR ANKYLOSING SPONDYLITIS: IMPROVEMENT OF AT LEAST 50%, OR 2 UNITS (SCALE OF 1-10), IN THE BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX (BASDAI) OR IMPROVEMENT OF AT LEAST 20% IN THE ASSESSMENT IN ANKYLOSING SPONDYLITIS (ASAS20) CRITERIA.AGE RESTRICTIONSPRESCRIBER RESTRICTIONS PRESCRIBED BY OR SUPERVISED BY A GASTROENTEROLOGIST, RHEUMATOLOGIST OR DERMATOLOGIST.COVERAGE DURATION UC: 12 MO. OTHER INDICATIONS INITIAL: 4 MO RENEWAL: 12 MOOTHER CRITERIA INITIAL: FOR MODERATE TO SEVERE CROHN'S DISEASE/ULCERATIVE COLITIS/ACUTE ENTEROCUTANEOUS FISTULA: TRIAL/FAILURE OF ONE OR MORE OF THE FOLLOWING PREFERRED THERAPY AGENTS SUCH AS SULFASALAZINE, NHE_PA_Webfile CORTICOSTEROIDS, AZATHIOPRINE, METHOTREXATE, OLSALAZINE, ASACOL, PENTASA, CYCLOSPORINE,OR MERCAPTOPURINE. FOR MODERATE TO SEVERE RHEUMATOID ARTHRITIS: TRIAL OF HUMIRA OR CIMZIA AND TRIAL/FAILURE TO AT LEAST ONE DMARD AGENT (METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE). FOR PSORIATIC ARTHRITIS: TRIAL OF HUMIRA AND TRIAL/FAILURE TO AT LEAST ONE DMARD AGENT (METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. FOR SEVERE PLAQUE PSORIASIS COVERING 10% BSA: TRIAL/FAILURE/INTOLERABLE SIDE AFFECTS TO AT LEAST ONE PREFERRED THERAPY (PUVA, UVB, ACITRETIN, METHOTREXATE OR CYCLOSPORINE).NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION INFUSIBLE DRUG BVD DETERMINATIONDRUG NAME ABELCET | ACYCLOVIR SODIUM | ADRIAMYCIN | AMPHOTERICIN B | BLEOMYCIN SULFATE | CLADRIBINE | CYTARABINE | FLUOROURACIL | FOSCARNET SODIUM | GANCICLOVIR SODIUM | HERCEPTIN | IFOSFAMIDE | METHOTREXATE | MITOMYCIN | REMODULIN | TORISEL | VINBLASTINE SULFATE | VINCRISTINE SULFATECOVERED USES THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATIONOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION INTERFERON AGENTS - INTERFERON ALFA-2BDRUG NAME INTRON ACOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. EXCLUSION CRITERIA DIAGNOSIS: HEPATITIS C: NOT IN COMBINATION WITH RIBAVIRIN UNLESS CONTRAINDICATED.REQUIRED MEDICAL INFORMATION HEP C: PRETREATMENT HCV RNA LEVEL GREATER THAN OR EQUAL TO 50 IU/ML. AGE RESTRICTIONSPRESCRIBER RESTRICTIONS HEP C: GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (E.G. HEPATOLOGIST).COVERAGE DURATION HEP C: GENOTYPE 1, 4, 5, OR 6: 4 MOS. 2 OR 3: 6 MOS. ALL OTHER INDICATIONS: 6 MOS. RENEWAL: 6 MOS.OTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION INTERFERON AGENTS - PEG-INTERFERON ALFA-2ADRUG NAME PEGASYS | PEGASYS PROCLICKCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION INITIAL: HEP C: PRETREATMENT HCV RNA LEVEL GREATER THAN OR EQUAL TO 50 IU/ML. RENEWAL: HEP C GENOTYPE 1, 4, 5, OR 6: WEEK 24 - HCV RNA UNDECTECTABLE (LESS THAN 50 IU/ML). WEEK 12 - 2-LOG REDUCTION IN QUANTITATIVE HCV RNA LEVEL OR HAS A HCV RNA DETECTABLE LEVEL GREATER THAN 50 IU/ML.AGE RESTRICTIONS 5 YEARS OR OLDER.PRESCRIBER RESTRICTIONS GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (E.G. HEPATOLOGIST).COVERAGE DURATION HEP B AND HEP C GENOTYPE 2, 3: 6 MONTHS. GENOTYPE 1, 4, 5, 6: 4-MONTHS.OTHER CRITERIA TRIAL OR CONTRAINDICATION TO PEGINTRON. DRUG MUST BE USED IN COMBINATION WITH RIBAVIRIN UNLESS CONTRAINDICATED.RENEWAL: HEP B: 6- MONTHS. HEP C: GENOTYPE 1, 4, 5, 6: WEEK 12 - TWO LOG REDUCTION IN QUANTITATIVE HCV OR HCV RNA GREATER THAN 50 IU/ML APPROVE 8 WEEKS. AT WEEK 24: HCV UNDECTECTABLE (LESS THAN 50 IU/ML: APPROVE 48 WEEKS. RENEWAL: HIV CO-INFECTION GENOTYPE 2, 3: TOTAL DURATION ALLOWED 48 WEEKS.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION INTERFERON AGENTS - PEG-INTERFERON ALFA-2BDRUG NAME PEGINTRON | PEGINTRON REDIPENCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION INITIAL: HEP C: PRETREATMENT HCV RNA LEVEL GREATER THAN OR EQUAL TO 50 IU/ML. RENEWAL: HEP C GENOTYPE 1, 4, 5, OR 6: WEEK 24 - HCV RNA UNDECTECTABLE (LESS THAN 50 IU/ML). WEEK 12 - 2-LOG REDUCTION IN QUANTITATIVE HCV RNA LEVEL OR HAS A HCV RNA DETECTABLE LEVEL GREATER THAN 50 IU/ML.AGE RESTRICTIONS 3 YEARS OR OLDER.PRESCRIBER RESTRICTIONS GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (E.G. HEPATOLOGIST).COVERAGE DURATION HEP C: GENOTYPE 2 OR 3: 6-MOS. GENOTYPE 1, 4, 5, 6: 4-MOS. MONOTHERAPY: 12 MOS.OTHER CRITERIA DRUG MUST BE USED IN COMBINATION WITH RIBAVIRIN UNLESS CONTRAINDICATED. RENEWAL: HEP C: GENOTYPE 1, 4, 5, 6: WEEK 12: TWO LOG REDUCTION IN QUANTITATIVE HCV OR HCV RNA GREATER THAN 50 IU/ML APPROVE 8 WEEKS. AT WEEK 24: HCV UNDECTECTABLE (LESS THAN 50 IU/ML: APPROVE 48 WEEKS. RENEWAL: HEPATITIS C: GENOTYPE 2 OR 3: NO RENEWAL.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION IPILIMUMABDRUG NAME YERVOYCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 3 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION IVACAFTORDRUG NAME KALYDECOCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION G551D MUTATIONAGE RESTRICTIONS 6 YEARS OF AGE OR OLDER.PRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION METHOTREXATE BVD DETERMINATIONDRUG NAME METHOTREXATE | TREXALLCOVERED USES THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATIONOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION METHYLNALTREXONEDRUG NAME RELISTORCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION CONSTIPATION DUE TO OPIOIDSAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION UP TO 6 MONTHSOTHER CRITERIA PATIENT IS RECEIVING PALLIATIVE CARE.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION MIFEPRISTONEDRUG NAME KORLYMCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION MIPOMERSENDRUG NAME KYNAMROCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIA LDL APHERESISREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA USE IN COMBINATION WITH OTHER LIPID LOWERING TREATMENTS SUCH AS A STATIN (EXAMPLE: SIMVASTATIN, ATORVASTATIN), FENOFIBRATE, NIACIN, ETC.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION MODAFINIL AND ARMODAFINILDRUG NAME MODAFINILCOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION NATALIZUMABDRUG NAME TYSABRICOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION MULTIPLE SCLEROSIS:12 MONTHS. CROHN'S DISEASE: 6 MONTHS. RENEWAL: CROHN'S: 12 MONTHS.OTHER CRITERIA MULTIPLE SCLEROSIS: TRIAL OF AN INTERFERON OR COPAXONE. CROHN'S DISEASE: TRIAL OF A TNF-ALPHA INHIBITOR. RENEWAL: CROHN'S: PATIENT IS NOT ON CONCOMITANT CORTICOSTEROID TREATMENT AFTER 6 MONTHS ON NATALIZUMAB, OR HAS NOT RECEIVED MORE THAN 3 MONTHS OF A CORTICOSTEROID WITHIN THE PAST 12 MONTHS.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION NEBULIZER BVD DETERMINATIONDRUG NAME ACETYLCYSTEINE | ALBUTEROL SULFATE | CROMOLYN SODIUM | PULMOZYME | TOBI | VENTAVISCOVERED USES THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATIONOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION OFATUMUMABDRUG NAME ARZERRACOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIA CHRONIC LYMPHOCYTIC LEUKEMIA: NO FAILED TREATMENT WITH FLUDARABINE AND ALEMTUZUMABREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 6 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION OMACETAXINEDRUG NAME SYNRIBOCOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION INDUCTION: 3 MONTHS. POST INDUCTION/RENEWAL: 3 TO 12 MONTHSOTHER CRITERIA DETERMINATION FOR THERAPY LENGTH OF APPROVAL THAT IS NOT INDUCTION THERAPY WILL DEPEND ON THE PATIENT HEMATOLOGIC RESPONSE (DEFINED AS ABSOLUTE NEUTROPHIL COUNT (ANC) GREATER THAN OR EQUAL TO 1.5 X 10^9/L AND PLATELETS GREATER THAN OR EQUAL TO 100 X 10^9/L AND NO BLOOD BLASTS OR BONE MARROW BLASTS LESS THAN 5%).NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION OMALIZUMABDRUG NAME XOLAIRCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION INITIAL: PATIENT MEETS THE CRITERIA OF MODERATE TO SEVERE ASTHMA, POSITIVE SKIN PRICK OR RAST TEST, FEV1 LESS THAN 80%, DEMONSTRATED INADEQUATELY CONTROLLED SYMPTOMS ON INHALED CORTICOSTEROIDS AND SECOND ASTHMA CONTROLLER, BASELINE IGE SERUM LEVEL GREATER THAN OR EQUAL TO 30 IU/ML. RENEWAL: PATIENT REDUCED EXACERBATIONS BY AT LEAST 25% FROM BASELINE, REDUCTION IN ORAL OR INHALED CORTICOSTEROID USE FROM BASELINE.AGE RESTRICTIONS PATIENT 12 YEARS OF AGE OR OLDERPRESCRIBER RESTRICTIONS SPECIALIST IN ALLERGY OR PULMONARY MEDICINE ONLYCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION OPIOID DEPENDENCY AGENTSDRUG NAME BUPRENORPHINE HCL | BUPRENORPHINE-NALOXONE | SUBOXONECOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION PSYCHOSOCIAL COUNSELINGAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION SUBUTEX: 1 MONTH SUBOXONE: 6 MONTHSOTHER CRITERIA CONTINUATION OF THERAPY WITH SUBUTEX: CONTRAINDICATION OR UNABLE TO TOLERATE NALOXONE IN COMBINATION WITH BUPRENORPHINE.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION PAZOPANIBDRUG NAME VOTRIENTCOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION PDE5 INHIBITORS FOR PULMONARY ARTERIAL HYPERTENSIONDRUG NAME ADCIRCA | REVATIO | SILDENAFILCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONS CARDIOLOGIST OR PULMONOLOGISTCOVERAGE DURATION 12 MONTHSOTHER CRITERIA REQUEST FOR ADCIRCA REQUIRE TRIAL OR CONTRAINDICATION TO REVATIO.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION PEG-INTERFERON ALFA-2B-SYLATRONDRUG NAME SYLATRONCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA CRITERIA APPLIES TO NEW STARTS ONLY. DURATION LIMITATION OF 5 YEARS OF THERAPY.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION PLERIXAFORDRUG NAME MOZOBILCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G- CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA AND MULTIPLE MYELOMAAGE RESTRICTIONSPRESCRIBER RESTRICTIONS HEMATOLOGIST OR ONCOLOGISTCOVERAGE DURATION 4 DOSES (UP TO 8 VIALS) FOR ONE FILL PER DAY.OTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION POMALIDOMIDEDRUG NAME POMALYSTCOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION PONATINIBDRUG NAME ICLUSIGCOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION PRAMLINTIDEDRUG NAME SYMLINPEN 120 | SYMLINPEN 60COVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION TYPE I OR TYPE II DIABETES: REQUIRING INSULIN OR CONTINUOUS INSULIN INFUSION (INSULIN PUMP) FOR GLYCEMIC CONTROLAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION QUININE SULFATEDRUG NAME QUININE SULFATECOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION RABIES VACCINE BVD DETERMINATIONDRUG NAME IMOVAX RABIES VACCINE | RABAVERTCOVERED USES THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATIONOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION REGORAFENIBDRUG NAME STIVARGACOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA TRIAL OR CONTRAINDICATION TO ANTI-EGFR THERAPY SUCH AS ERBITUX OR VECTIBIX. TRIAL OR CONTRAINDICATION TO ANTI-VEGF THERAPY SUCH AS AVASTIN OR ZALTRAP AND A FLUOROPYRMIDE-, OXAPLATIN- AND IRINOTECAN- BASED CHEMOTHERAPY SUCH AS FOLFOX, FOLFIRI,CAPEOX, INFUSIONAL 5-FU/LV OR CAPECITABINE, AND FOLFOXIRI.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION RIFAXIMINDRUG NAME XIFAXANCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONS TRAVELERS' DIARRHEA: 12 YEARS OR OLDER. HEPATIC ENCEPHALOPATHY: 18 YEARS OR OLDER.PRESCRIBER RESTRICTIONSCOVERAGE DURATION TRAVELERS' DIARRHEA: 1 FILL IN 1 MONTH. HEPATIC ENCEPHALOPATHY: 12 MONTHS.OTHER CRITERIA TRAVELERS' DIARRHEA: TRIAL OF CIPROFLOXACIN OR AZITHROMYCIN. HEPATIC ENCEPHALOPATHY: TRIAL OF LACTULOSE MONOTHERAPY.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION RITUXIMABDRUG NAME RITUXANCOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION RENEWAL: ACTIVE RHEUMATOID ARTHRITIS/PSORIATIC ARTHRITIS: GREATER THAN 20% IMPROVEMENT IN TENDER JOINT COUNT AND SWOLLEN JOINT COUNT. AGE RESTRICTIONSPRESCRIBER RESTRICTIONS PRESCRIBED BY OR SUPERVISED BY: FOR RHEUMATOID ARTHRITIS A RHEUMATOLOGIST. FOR NHL OR CLL AN ONCOLOGIST.COVERAGE DURATION RA: INITIAL AND RENEWAL 4 MO. HNL: 1 YEAR. CLL: 6 MO. WG, MPA: 1 MO.OTHER CRITERIA INITIAL: RHEUMATOID ARTHRITIS: CURRENTLY TAKING OR HAVE A CONTRAINDICATION TO THE USE OF METHOTREXATE AND TRIAL/FAILURE OF ONE TNF BLOCKER (ENBREL, HUMIRA, SIMPONI, CIMZIA). NON HODGKIN'S LYMPHOMA/CHRONIC LYMPHOCYTIC LEUKEMIA: USED IN COMBINATION WITH CHEMOTHERAPY. WEGNER'S GRANULOMATOSIS/MICROSCOPIC POLYANGIITIS: CONCURRENT GLUCOCORTICOID USE.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION ROMIDEPSINDRUG NAME ISTODAXCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA TRIAL OF OR CONTRAINDICATION TO VORINOSTAT (ZOLINZA) AND NOT ABLE TO TOLERATE ORAL MEDICATIONS, OR IS ABLE TO TOLERATE ORAL MEDICATIONS AND HAS TRIED AT LEAST ONE SYSTEMIC THERAPY (RETINOID, INTERFERON, EXTRACORPOREAL PHOTOPHERESIS, DENILEUKIN DIFTITOX, METHOTREXATE, LIPOSOMAL DOXORUBICIN, GEMCITABINE, CHLORAMBUCIL, PENTOSTATIN, ETOPOSIDE, CYCLOPHOSPHAMIDE, TEMOZOLOMIDE, BORTEZOMIB).NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION RUXOLITINIBDRUG NAME JAKAFICOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION RENEWAL: IMPROVEMENT OR MAINTENANCE OF SYMPTOM IMPROVEMENT SUCH AS A 50% OR GREATER REDUCTION IN TOTAL SYMPTOM SCORE ON THE MODIFIED MYELOFIBROSIS SYMPTOM ASSESSMENT FORM (MFSAF) V2.0 OR 50% OR GREATER REDUCTION IN PALPABLE SPLEEN LENGTH, OR REDUCTION OF 35% OR GREATER FROM BASELINE SPLEEN VOLUME AFTER 6 MONTHS OF THERAPY.AGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION INITIAL: 6 MONTHS. RENEWAL: 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION SOMATROPINDRUG NAME GENOTROPIN | HUMATROPE | NORDITROPIN FLEXPRO | NORDITROPIN NORDIFLEX | NUTROPIN | NUTROPIN AQ | NUTROPIN AQ NUSPIN | OMNITROPE | SAIZEN | SEROSTIM | TEV-TROPIN | ZORBTIVECOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS.EXCLUSION CRITERIA ATHLETIC ENHANCEMENT OR ANTI-AGING PURPOSE. GROWTH FAILURE DUE TO CHRONIC RENAL INSUFFICIENCY(CRI) IF PATIENT HAS HAD A RENAL TRANSPLANTREQUIRED MEDICAL INFORMATION FOR GROWTH FAILURE DUE TO (CRI): PATIENT HAS NOT UNDERGONE A RENAL TRANSPLANT, PATIENT'S HEIGHT AT LEAST 2 STANDARD DEVIATIONS (SD) BELOW THE MEAN HEIGHT FOR NORMAL CHILDREN OF THE SAME AGE AND GENDER, LACK OF RESPONSE FROM PREVIOUS YEAR, PATIENT HAS REACHED 50TH PERCENTILE FOR TARGET HEIGHT FOLLOWING GROWTH HORMONE THERAPY. FOR HIV/WASTING: THE PATIENT ON ANTIRETROVIRAL THERAPY, MEETS CRITERA OF WEIGHT LOSS: 10% UNINTENTIONAL WEIGHT LOSS OVER 12 MONTHS, 7.5% OVER 6 MONTHS, 5% BODY CELL MASS (BCM) LOSS WITHIN 6 MONTHS, OR A BCM LESS THAN 35% (MEN) OR 23% (WOMEN) OF TOTAL BODY WT. AND A BODY MASS INDEX (BMI) LESS THAN 27KG/M2, OR BMI LESS THAN 20KG/M2. IF CURRENTLY ON GROWTH HORMONE, PATIENT HAS SHOWN CLINICAL BENEFIT IN MUSCLE MASS AND WEIGHT OR IF NOT ON GROWTH HORMONE, PATIENT HAS HAD INADEQUATE RESPONSE TO PREVIOUS THERAPY. (I.E. EXERCISE TRAINING, NUTRITIONAL SUPPLEMENTS, APPETITE STIMULANTS OR ANABOLIC STEROIDS). FOR SHORT-BOWEL SYNDROME: CURRENTLY ON SPECIALIZED NUTRITIONAL SUPPORT.AGE RESTRICTIONSPRESCRIBER RESTRICTIONSNHE_PA_Webfile COVERAGE DURATION HIV/AIDS: 3 MONTHS. SHORT BOWEL: 4 WEEK ONCE. ALL OTHER DIAGNOSES: 12 MONTHS.OTHER CRITERIA FOR NON PART INDICATONS: COVERED FOR PATIENTS DIAGNOSED WITH CACHEXIA SECONDARY TO CONDITIONS OTHER THAN AIDSNHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION SORAFENIB TOSYLATEDRUG NAME NEXAVARCOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION SUNITINIB MALATEDRUG NAME SUTENTCOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA GASTROINTESTIONAL STROMAL TUMORS (GIST): TRIAL OF OR CONTRAINDICATION TO GLEEVEC.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION TELAPREVIRDRUG NAME INCIVEKCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION CHRONIC HEPATITIS C, GENOTYPE 1. HCV RNA LEVEL/VIRAL LOAD OF LESS THAN 1,000 IU/ML AT 4 WEEKS OF TELAPREVIR THERAPY.AGE RESTRICTIONS PATIENT 18 YEARS OF AGE OR OLDER.PRESCRIBER RESTRICTIONS GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (E.G. HEPATOLOGIST) OR SPECIALLY TRAINED GROUP (E.G. EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES).COVERAGE DURATION 12 WEEKSOTHER CRITERIA CONCURRENT USE OF RIBAVIRIN AND PEGINTERFERON ALFA. PATIENT HAS NOT FAILED PRIOR THERAPY WITH TELAPREVIR (INCIVEK) OR BOCEPREVIR (VICTRELIS). CURRENTLY NOT TAKING RIFAMPIN. DOES NOT CURRENTLY HAVE A CO-INFECTION WITH HEPATITIS B, OR HISTORY OF PREVIOUS SOLID ORGAN TRANSPLANT.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION TERIFLUNOMIDEDRUG NAME AUBAGIOCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA TRIAL OF OR CONTRAINDICATION TO ONE INTERFERON THERAPY (SUCH AS AVONEX, BETASERON, EXTAVIA, OR REBIF) AND TO COPAXONE.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION TERIPARATIDEDRUG NAME FORTEOCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIA GREATER THAN 24 MONTHS OF THERAPY.REQUIRED MEDICAL INFORMATION A PATIENT WITH EITHER A DIAGNOSIS OF SEVERE OSTEOPOROSIS (T-SCORE LESS THAN -2.5 WITH FRAGILITY FRACTURE) OR A T SCORE EQUAL TO OR LESS THAN -2.5 AND MULTIPLE RISK FACTORS FOR FRACTURE (E.G. HISTORY OF MULTIPLE RECENT LOW TRAUMA FRACTURES, CORTICOSTEROID USE, OR USE OF GNRH ANALOGS), OR FAILED AN ADEQUATE TRIAL OF BISPHOSPHONATES, IS INTOLERANT, OR HAS A CONTRAINDICATION TO BISPHOSPHONATES.AGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION TESTOSTERONEDRUG NAME TESTOSTERONE CYPIONATE | TESTOSTERONE ENANTHATECOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION CURRENTLY RECEIVING TESTOSTERONE REPLACMENT. MALE HYPOGONADISM CONFIRMED BY EITHER: 1) LABORATORY CONFIRMED TOTAL SERUM TESTOSTERONE LEVEL OF LESS THAN 300 NG/DL OR 2) A LOW TOTAL SERUM TESTOSTERONE LEVEL AS INDICATED BY A LAB RESULT WITH A REFERENCE RANGE OBTAINED WITHIN 90 DAYS, OR 3) A FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 50NG/L OR 4) MALE DELAYED PUBERTY NOT SECONDARY TO PATHOLOGY.AGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA RENEWAL: MALE HYPOGONADISM: CONTINUATION OF THERAPY WITH FDA APPROVED INDICATION AND RECORDED HISTORY OF PREVIOUS TESTOSTERONE REPLACEMENT THERAPY.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION TETANUS TOXOID VACCINE BVD DETERMINATIONDRUG NAME TETANUS TOXOID ADSORBEDCOVERED USES THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATIONOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION TETRABENAZINEDRUG NAME XENAZINECOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONS NEUROLOGISTCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION THIAZOLIDINEDIONEDRUG NAME AVANDAMET | AVANDARYL | AVANDIACOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA APPLIES TO NEW STARTS ONLY. TRIAL OR CONTRAINDICATION TO METFORMIN, METFORMIN ER, GLYBURIDE/METFORMIN, GLIPIZIDE/METFORMIN OR A SULFONYLUREA AND PIOGLITAZONE.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION TOCILIZUMABDRUG NAME ACTEMRACOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION DIAGNOSIS: ACTIVE RHEUMATOID ARTHRITIS. RENEWAL: AT LEAST 20% IMPROVEMENT IN TENDER JOINT COUNT AND SWOLLEN JOINT COUNT. AGE RESTRICTIONSPRESCRIBER RESTRICTIONS RHEUMATOLOGISTCOVERAGE DURATION INITIAL: 6 MONTHS. RENEWAL: 6 MONTHSOTHER CRITERIA TRIAL OF OR CONTRAINDICATION TO AT LEAST ONE OF THE FOLLOWING: ENBREL, HUMIRA, REMICADE, SIMPONI OR CIMZIA.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION TOFACITINIBDRUG NAME XELJANZCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION RHEUMATOID ARTHRITIS RENEWAL: PATIENT HAS EXPERIENCED OR MAINTAINED A 20% IMPROVEMENT IN TENDER OR SWOLLEN JOINT COUNT WHILE ON THERAPY.AGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION INITIAL: 3 MONTHS. RENEWAL: 12 MONTHSOTHER CRITERIA RHEUMATOID ARTHRITIS INITIAL THERAPY: TRIAL OR CONTRAINDICATION TO HUMIRA (ADALIMUMAB) AND CIMZIA (CERTOLIZUMAB PEGOL).NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION TOPICAL TRETINOINDRUG NAME AVITA | TRETINOINCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIA WRINKLES, PHOTOAGING, MELASMA.REQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA BRAND TRETINON WILL REQUIRE TRIAL OF GENERIC TOPICAL TRETINOIN.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION TOTAL PARENTARAL NUTRITION AGENT BVD DETERMINATIONDRUG NAME AMINOSYN | AMINOSYN II | AMINOSYN M | AMINOSYN-HBC | AMINOSYN-PF | CLINIMIX | CLINIMIX E | CLINISOL | DEXTROSE IN WATER | FREAMINE III | FREAMINE III WITH ELECTROLYTES | HEPATAMINE | HEPATASOL | INTRALIPID | LIPOSYN III | NEPHRAMINE | PREMASOL | PROCALAMINE | PROSOL | TRAVASOL | TROPHAMINECOVERED USES THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATIONOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION TRAMETINIB DIMETHYL SULFOXIDEDRUG NAME MEKINISTCOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION TRASTUZUMABDRUG NAME KADCYLACOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION USTEKINUMABDRUG NAME STELARACOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION INITIAL: PLAQUE PSORIASIS: MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 10 PERCENT BODY SURFACE AREA OR PASI SCORE GREATER THAN OR EQUAL TO 12. PATIENT'S WEIGHT. AGE RESTRICTIONSPRESCRIBER RESTRICTIONS DERMATOLOGIST OR RHEUMATOLOGIST COVERAGE DURATION INITIAL: 4 MONTHS. RENEWAL: 12 MONTHSOTHER CRITERIA FOR SEVERE PLAQUE PSORIASIS COVERING 10% BSA: TRIAL/FAILURE/INTOLERABLE SIDE AFFECTS TO AT LEAST ONE PREFERRED THERAPY (PUVA, UVB, ACITRETIN, METHOTREXATE OR CYCLOSPORINE). RENEWAL: PHYSICIAN'S GLOBAL ASSESMENT EQUAL TO ZERO OR ONE OR A DECREASE OF PASI OF AT LEAST 50% OR GREATER.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION VANDETANIBDRUG NAME CAPRELSACOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA CRITERIA APPLIES TO NEW STARTS ONLY.NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION VEMURAFENIBDRUG NAME ZELBORAFCOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATION BRAFV600E MUTATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION VILAZODONEDRUG NAME VIIBRYDCOVERED USES ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIA TRIAL OF OR CONTRAINDICATION TO A SSRI (PAROXETINE, SERTARLINE, CITALOPRAM, FLUOXETINE, OR ESCITALOPRAM) AND A SECOND AGENT (BUPROPION HCL (IR, SR, OR XL), MIRTAZAPINE, OR VENLAFAXINE (IR OR XR)).NHE_PA_Webfile Network Health Unify Prior Authorization Requirements Effective Date: 11/01/2013PRIOR AUTHORIZATION GROUP DESCRIPTION VISMODEGIBDRUG NAME ERIVEDGECOVERED USES ALL MEDICALLY ACCEPTED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.EXCLUSION CRITERIAREQUIRED MEDICAL INFORMATIONAGE RESTRICTIONSPRESCRIBER RESTRICTIONSCOVERAGE DURATION 12 MONTHSOTHER CRITERIANHE_PA_Webfile

Prior Authorization Group Description

Details

Download

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

Support